Page 35 - Product Testing News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Idorsia submits NDA for clazosentan to Japanese PMDA Idorsia Pharmaceuticals LtdMarch 1, 2021 GMT Allschwil, Switzerland – March 1, 2021 Idorsia Ltd (SIX: IDIA) today announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for clazosentan, a fast-acting, selective endothelin A (ETA) receptor antagonist, for the prevention of cerebra...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Stop & Shop Kicks Off Annual ‘Help Cure Childhood Cancer’ Campaign Stop and ShopMarch 1, 2021 GMT QUINCY, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Stop & Shop today announced the start of its annual ‘Help Cure Childhood Cancer’ campaign to support Dana-Farber Cancer Institute and the Jimmy Fund in Massachusetts and MSK Kids, the Pediatrics Program at Memorial Sloan Kettering Cancer Center in ...

CHICAGO, March 2, 2021 /PRNewswire/ -- Findings from two national surveys appearing in the Alzheimer’s Association 2021 Alzheimer’s Disease Facts and Figures report reveal that discrimination is a barrier to Alzheimer’s and dementia care. More than one-third of Black Americans (36%), and nearly one-fifth of Hispanic Americans (18%) and Asian Americans (19%), believes discrimination would be a barrier to receiving Alzheimer’s care. In addition, half or more of non-White caregivers say th...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Highlight & Pivotal start Phase IIa melanoma trial Highlight TherapeuticsMarch 2, 2021 GMT Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety Trial will examine administration of Highlight’s BO-112 in combination with an anti-PD1 in unresectable or metastatic melanoma patients Recruitment has already begun across ...

Press release content from Business Wire. The AP news staff was not involved in its creation. FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc. March 2, 2021 GMT WEST CHESTER, Pa.--(BUSINESS WIRE)--Mar 2, 2021-- Molecular Targeting Technologies, Inc. (MTTI), a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the approval of an Investigational New Drug (IND) application by th...

Press release content from Accesswire. The AP news staff was not involved in its creation.

Press release content from PR Newswire. The AP news staff was not involved in its creation. Innova Medical Group Announces New Chairman and Chief Medical Officer March 1, 2021 GMT PASADENA, Calif., Mar. 1, 2021 /PRNewswire/ -- Innova Medical Group, Inc., the world’s largest manufacturer of rapid antigen test kits and leader in COVID-19 testing solutions globally, announced today the appointment of Sean Rogers as Chairman of Innova Medical Group, and Todd Malan, M.D., as Innova’s Chief Medic...

Press release content from Business Wire. The AP news staff was not involved in its creation. Tezepelumab Is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients February 26, 2021 GMT WILMINGTON, Del.--(BUSINESS WIRE)--Feb 26, 2021-- Positive full results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab demonstrated a statistically significant and clinically meaningful 1 reduction in the an...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer Nabriva Therapeutics US, IncFebruary 26, 2021 GMT DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appoi...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand ... Pharvaris N.V.February 26, 2021 GMT ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-re...